These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 23303639)

  • 21. Protein glutathionylation increases in the liver of patients with non-alcoholic fatty liver disease.
    Piemonte F; Petrini S; Gaeta LM; Tozzi G; Bertini E; Devito R; Boldrini R; Marcellini M; Ciacco E; Nobili V
    J Gastroenterol Hepatol; 2008 Aug; 23(8 Pt 2):e457-64. PubMed ID: 17683488
    [TBL] [Abstract][Full Text] [Related]  

  • 22. "Let there be bile"--understanding hepatic injury in cholestasis.
    Sokol RJ; Devereaux M; Dahl R; Gumpricht E
    J Pediatr Gastroenterol Nutr; 2006 Jul; 43 Suppl 1():S4-9. PubMed ID: 16819400
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug disposition in liver disease.
    Fruncillo RJ
    Am Fam Physician; 1982 Dec; 26(6):167-9. PubMed ID: 7148640
    [No Abstract]   [Full Text] [Related]  

  • 24. Curcumin prevents chronic alcohol-induced liver disease involving decreasing ROS generation and enhancing antioxidative capacity.
    Rong S; Zhao Y; Bao W; Xiao X; Wang D; Nussler AK; Yan H; Yao P; Liu L
    Phytomedicine; 2012 Apr; 19(6):545-50. PubMed ID: 22445643
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis.
    Marra F; Gastaldelli A; Svegliati Baroni G; Tell G; Tiribelli C
    Trends Mol Med; 2008 Feb; 14(2):72-81. PubMed ID: 18218340
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-carcinogenic action of curcumin by activation of antioxidant defence system and inhibition of NF-κB signalling in lymphoma-bearing mice.
    Das L; Vinayak M
    Biosci Rep; 2012 Apr; 32(2):161-70. PubMed ID: 21831045
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Long-term therapy of liver diseases].
    Markoff N
    Wien Med Wochenschr; 1972 Feb; 122(7):95-9. PubMed ID: 4621921
    [No Abstract]   [Full Text] [Related]  

  • 28. The protective effect of curcumin on ischemia-reperfusion-induced liver injury.
    Lin CM; Lee JF; Chiang LL; Chen CF; Wang D; Su CL
    Transplant Proc; 2012 May; 44(4):974-7. PubMed ID: 22564600
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Positive effect of curcumin on inflammation and mitochondrial dysfunction in obese mice with liver steatosis.
    Kuo JJ; Chang HH; Tsai TH; Lee TY
    Int J Mol Med; 2012 Sep; 30(3):673-9. PubMed ID: 22751848
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TNF-alpha as therapeutic target in NASH: tried, but not yet proven.
    Chitturi S; Farrell GC
    J Gastroenterol Hepatol; 2007 May; 22(5):613-4. PubMed ID: 17444846
    [No Abstract]   [Full Text] [Related]  

  • 31. Can Nutraceuticals Support the Treatment of MASLD/MASH, and thus Affect the Process of Liver Fibrosis?
    Sokal-Dembowska A; Jarmakiewicz-Czaja S; Ferenc K; Filip R
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791276
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detoxification and antioxidant effects of curcumin in rats experimentally exposed to mercury.
    Agarwal R; Goel SK; Behari JR
    J Appl Toxicol; 2010 Jul; 30(5):457-68. PubMed ID: 20229497
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Up-regulation of aldose reductase expression mediated by phosphatidylinositol 3-kinase/Akt and Nrf2 is involved in the protective effect of curcumin against oxidative damage.
    Kang ES; Woo IS; Kim HJ; Eun SY; Paek KS; Kim HJ; Chang KC; Lee JH; Lee HT; Kim JH; Nishinaka T; Yabe-Nishimura C; Seo HG
    Free Radic Biol Med; 2007 Aug; 43(4):535-45. PubMed ID: 17640564
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vitamin E in chronic liver diseases and liver fibrosis.
    Di Sario A; Candelaresi C; Omenetti A; Benedetti A
    Vitam Horm; 2007; 76():551-73. PubMed ID: 17628189
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protective effect of curcumin on cypermethrin-induced oxidative stress in Wistar rats.
    Sankar P; Telang AG; Manimaran A
    Exp Toxicol Pathol; 2012 Jul; 64(5):487-93. PubMed ID: 21130633
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical aspects of bile acid metabolism in liver diseases.
    Iwamura K
    Tokai J Exp Clin Med; 1982 Jan; 7(1):7-29. PubMed ID: 6281949
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The evolving role of leptin and adiponectin in chronic liver diseases.
    Tsochatzis E; Papatheodoridis GV; Archimandritis AJ
    Am J Gastroenterol; 2006 Nov; 101(11):2629-40. PubMed ID: 16952281
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug development for liver diseases: focus on picroliv, ellagic acid and curcumin.
    Girish C; Pradhan SC
    Fundam Clin Pharmacol; 2008 Dec; 22(6):623-32. PubMed ID: 19049667
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protective role of curcumin on colchicine-induced cognitive dysfunction and oxidative stress in rats.
    Khurana S; Jain S; Mediratta PK; Banerjee BD; Sharma KK
    Hum Exp Toxicol; 2012 Jul; 31(7):686-97. PubMed ID: 22262262
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protective role of antioxidative food factors in oxidative stress caused by hyperglycemia.
    Osawa T; Kato Y
    Ann N Y Acad Sci; 2005 Jun; 1043():440-51. PubMed ID: 16037265
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.